Previous 10 | Next 10 |
Ofer Gonen, current Board member and CEO of Clal Biotechnology Industries Ltd., appointed as New CEO – Effective June 30 Will replace current CEO Sharon Malka, who will join the Board of Directors YAVNE, Israel, May 17, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasda...
Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds On track for NexoBrid BLA resubmission by mid-year Conference C all B egins T oday at 8:30 am ET YAVNE, Israel, May 17, 2022 (GLOBE NE...
MediWound (NASDAQ:MDWD) is scheduled to announce Q1 earnings results on Tuesday, May 17th, before market open. The consensus EPS Estimate is -$0.11 (-10.0% Y/Y) and the consensus Revenue Estimate is $4.29M (-26.7% Y/Y). Over the last 1 year, MDWD has beaten EPS estimates 75% of the time and h...
Study Met Primary and Key Secondary Endpoints with Statistically Significant Results Compared to Control Arms Significant Improvement Across Multiple Measures Over the Current Non-Surgical Standard-of Care No Deleterious Effect on Wound Closure and No Observed Safety I...
YAVNE, Israel, May 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the fi...
YAVNE, Israel, April 12, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that clinical data from the Company’s EscharEx ®...
Gainers: Sabre Corporation (SABR) +11%. Kura Sushi USA (KRUS) +11%. WD-40 Company (WDFC) +10%. MediWound (MDWD) +7%. Cognyte Software (CGNT) +5%. Losers: OraSure Technologies (OSUR) -5%. Momentus (MNTS) -5%. Icosavax (ICVX) -5%. Berkeley ...
Results Highlight the Safety and Efficacy in Hard-to-Heal Wounds SAWC to Take Place in Phoenix, Arizona on April 6-10, 2022 YAVNE, Israel, March 29, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generat...
YAVNE, Israel, March 22, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration, today announ...
Primary Endpoint Met with Highly Statistically Significant Results Final Data Readout Expected in Second Quarter of 2022 YAVNE, Israel, March 21, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio...
News, Short Squeeze, Breakout and More Instantly...
Research Published in THE LANCET's eClinicalMedicine EscharEx ® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue YAVNE, Israel, July 29, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in ne...
Funds to be used for clinical development of EscharEx ® to treat diabetic foot ulcers (DFUs) Award advances MediWound’s DFU program and its future revenues four years ahead of original schedule YAVNE, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd....
Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd PR Newswire GOTHENBURG, Sweden , July 15, 2024 /PRNewswire/ -- Mölnlycke Health Care, a world-leading MedTech company specialising i...